Radiopharmaceutical provider Ion Beam Applications (IBA) benefited from increasing market adoption and expanded use of proton therapy treatment, increasing revenues for sales and services by 8.8% during its 2012 fiscal year compared with 2011.
IBA reported revenues of 221.1 million euros ($286.7 million U.S.), compared with 203.2 million euros ($264.5 million) in fiscal year 2011. The Belgian company attributed the revenue increase in part to the sale of seven proton therapy rooms in 2012.
The year's net loss was 5.8 million euros ($7.5 million), due mostly to write-downs of a project and the restructuring of expenses. This was a considerable improvement compared with the 84.1 million euro loss ($109.06 million) the company experienced the year before.
The firm's operating margins rose to 7.6% in fiscal 2012 from 4.0% in fiscal 2012. The company has implemented an efficiency program with the goal of generating an annual savings of 10 million euros ($13 million) by 2014.
The Belgian company said that with the development of its Proteus One, a smaller, less expensive proton therapy system, it was attracting customers throughout the world who were interested in acquiring an easier to install, more cost-effective proton treatment facilities.
